Patients with a locally advanced or metastatic solid tumor cancers are needed for a study to research an investigational immunotherapy

IRB/UVA Tracking #
Principal Investigator
Matthew J Reilley
Sallie Mannen
Contact Email
Contact Phone
Official Trial Title
An open-label multicenter phase Ib study of AN0025 in combination with Pembrolizumab in patients with advanced solid tumors
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have a breast, non-small cell lung cancer, bladder, cervical, or colorectal cancers. The purpose of this study to evaluate an investigational drug (AN0025) plus an FDA approved drug (pembrolizumab) in patients with the 5 solid tumor cancer types. The experimental drug dose, safety, and the effects of the drug will be evaluated for this study.

Participation of drug treatment may last up to 2 years, longer, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here:


Up to $50 per study visit. Reimbursement: Up to $200 for hotel stay per night.